Cell Targeting Overview

  • Founded
  • 2004

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.4M

Cell Targeting General Information

Description

Developer of a stem cell technology intended to take cell therapy products to a new level of performance. The company's stem cell technology uses peptides to coat therapeutic cells using techniques that do not modify cell physiology, enabling users to elevated performance of cell therapy products.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • Cleveland, OH
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cell Targeting Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 28-Jan-2011 $2.4M 000 00.00 Completed Generating Revenue
3. Angel (individual) 01-Apr-2008 000 000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Grant Completed Startup
To view Cell Targeting’s complete valuation and funding history, request access »

Cell Targeting Patents

Cell Targeting Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-8580749-B2 Peptide-coated cell localization to diseased or damaged tissues and methods related thereto Inactive 05-Jun-2009 000000000 00
US-20100310531-A1 Peptide-coated cell localization to diseased or damaged tissues and methods related thereto Active 05-Jun-2009 000000000 00

Cell Targeting Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Defense Advanced Research Projects Agency Government 000 0000 000000 0
Global Cardiovascular Innovation Center Accelerator/Incubator Minority 000 0000 000000 0
The Toucan Project Venture Capital Minority 000 0000 000000 0
To view Cell Targeting’s complete investors history, request access »